Table 3.

Associations of the VEGF genotypes with tumor characteristics in the Swedish population

Polymorphism/genotype*
−634G/C−2578C/A
GG (%)GC (%)CC (%)CC (%)CA (%)AA (%)
Tumor size (mm)
    ≤20271 (53.8)194 (38.5)39 (7.7)138 (27.3)238 (47.0)130 (25.7)
    >20101 (43.5)99 (42.7)32 (13.8)73 (30.9)106 (44.9)57 (24.2)
    OR (95%Cl)1.001.37 (0.97-1.94)2.20 (1.27-3.82)1.000.84 (0.58-1.23)0.83 (0.53-1.29)
    P0.080.0040.410.44
Histologic grade
    Grade 179 (57.2)51 (37.0)8 (5.8)28 (20.4)67 (48.9)42 (30.7)
    Grade 2164 (52.1)126 (40.0)25 (7.9)90 (28.7)147 (46.8)77 (24.5)
    Grade 3111 (46.2)96 (40.0)33 (13.8)77 (31.4)114 (46.5)54 (22.0)
    Ptrend0.440.0090.190.04
Stage
    0 + I206 (48.8)174 (41.2)42 (10.0)118 (27.8)208 (49.1)98 (23.1)
    II-IV183 (53.5)130 (38.0)29 (8.5)96 (27.7)159 (46.0)91 (26.3)
    OR (95%Cl)1.000.84 (0.61-1.15)0.78 (0.45-1.34)1.000.94 (0.66-1.34)1.14 (0.76-1.72)
    P0.300.400.780.58
Regional lymph node metastasis
    Negative281 (50.2)224 (40.0)55 (9.8)158 (28.2)266 (47.4)137 (24.4)
    Positive114 (49.4)92 (40.8)25 (10.8)65 (28.3)116 (50.4)49 (21.3)
    OR (95%Cl)1.001.01 (0.72-1.42)1.12 (0.64-1.94)1.001.06 (0.73-1.55)0.87 (0.55-1.38)
    P0.990.770.820.60
Distant metastasis
    Negative377 (50.5)297 (39.8)72 (9.7)211 (28.1)353 (46.9)188 (25.0)
    Positive8 (72.7)1 (9.1)2 (18.2)5 (45.5)4 (36.4)2 (18.2)
    OR (95%Cl)1.000.16 (0.00-1.20)1.31 (0.13-6.74)1.000.48 (0.09-2.25)0.45 (0.04-2.79)
    P0.080.670.310.46
Estrogen receptors
    Positive158 (45.0)153 (43.6)40 (11.4)110 (31.3)162 (46.0)80 (22.7)
    Negative75 (56.0)45 (33.6)14 (10.4)44 (31.9)58 (42.0)36 (26.1)
    OR (95%Cl)1.000.62 (0.39-0.97)0.74 (0.36-1.50)1.000.90 (0.55-1.46)1.13 (0.64-1.97)
    P0.040.460.720.76
Progesterone receptors
    Positive123 (45.2)119 (43.8)30 (11.0)85 (29.5)121 (44.5)66 (24.3)
    Negative78 (51.7)59 (39.1)14 (9.3)46 (29.5)73 (46.8)37 (23.7)
    OR (95%Cl)1.000.78 (0.50-1.22)0.74 (0.35-1.55)1.001.11 (0.68-1.82)1.04 (0.58-1.84)
    P0.300.490.730.99
  • Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.

  • * Comparison with the genotype indicated by an odds ratio of 1.00.

  • 54% of samples were stage I and 41% were stage II.

  • Fisher exact test.